Church & Dwight heads into its July 31 Q2 earnings report with the stock up 4.4% on the week and short sellers showing no sign of pressing their case.
The positioning picture is broadly relaxed. Short interest has drifted slightly lower over the past month, now at 4.4% of the free float — not a crowded trade by any measure. Borrow availability is exceptionally loose, running at roughly 2,529% of current short interest, meaning there are around 13 shares available to borrow for every one already lent out. Cost to borrow has eased to about 0.52%, close to its cheapest level in weeks. Options markets are mildly more cautious than usual — the put/call ratio edged up to 0.26, just over one standard deviation above its 20-day average — but remains call-heavy by any historical standard, with the 52-week high PCR sitting at 1.46. The stock closed at $99.93, recovering ground it lost after a 4.3% drop following the prior Q1 print in May.
The analyst debate is less about the direction of travel and more about how much the stock deserves to re-rate. Barclays remains a sceptic, raising its target to $86 while holding its Underweight rating on July 21 — a price that sits roughly 14% below where the stock trades now. JP Morgan and UBS are closer to market, both Neutral with targets of $105 and $104 respectively after lifting them earlier this month. Wells Fargo carries the most constructive active view at Overweight with a $110 target. RBC's Outperform at $114 is the high end of the board. The mean target of about $104 implies only 4% upside from current levels — thin for a stock trading at a PE of 25x. The bull case rests on Church & Dwight's consumer staple positioning: Arm & Hammer, OxiClean, and Vitafusion benefit when households trade down. Bears point to concentrated US exposure — around 80% of sales — rising cost pressures, and relatively modest pricing power versus larger peers.
Insider selling has been persistent in recent months. Multiple executives, including the Lead Independent Director and an EVP, sold shares in June at prices around $98, and the CFO trimmed in March. Net insider sales over the past 90 days reached roughly $4.8 million. None of the transactions were enormous relative to company size, and they carry low trade-significance scores, but the directional pattern is uniformly one way. On the institutional side, BlackRock added modestly in Q2 while JP Morgan Asset Management built a more meaningful position.
Thursday's print will test whether the stock's 14.7% year-to-date gain is justified by organic volume growth and margin delivery — or whether the re-rating has run ahead of fundamentals that Barclays and the sell-side's Neutral camp believe are more modest than the price implies.
See the live data behind this article on ORTEX.
Open CHD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
